期刊
CANADIAN JOURNAL OF GASTROENTEROLOGY
卷 26, 期 7, 页码 457-462出版社
PULSUS GROUP INC
DOI: 10.1155/2012/213828
关键词
Clostridium difficile; Fecal microbial therapy; Microbiome
资金
- CIHR
- Institute of Infection and Immunity
- Institute of Nutrition, Metabolism, and Diabetes
- Gastrointestinal Diseases Research Unit at Queen's University
A working group from across Canada comprised of clinician and basic scientists, epidemiologists, ethicists, Health Canada regulatory authorities and representatives of major funding agencies (Canadian Institutes of Health Research and the Crohn's and Colitis Foundation of Canada) met to review the current experience with fecal microbial therapy and to identify the key areas of study required to move this field forward. The report highlights the promise of fecal microbial therapy and related synthetic stool therapy (together called 'microbial ecosystems therapeutics') for the treatment of Clostridium difficile colitis and, possibly, other disorders. It identifies pressing clinical issues that need to be addressed as well as social, ethical and regulatory barriers to the use of these important therapies.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据